Oncogenic activation of the PI3K signaling could be mutually influenced by the hepatocyte growth factor (HGF)/MET axis, the programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) axis, and microsatellite instability triggered by mismatch repair deficiency (MSI/dMMR), the regulation of which, in our understanding, can contribute to BC treatment [13]. The gene discussed is MET; the disease is breast cancer.